Literature DB >> 24080647

GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration.

Pedro Miguel Salcedo Gómez1, Masayuki Amano, Sofiya Yashchuk, Akira Mizuno, Debananda Das, Arun K Ghosh, Hiroaki Mitsuya.   

Abstract

We designed, synthesized, and identified two novel nonpeptidic human immunodeficiency virus type 1 (HIV-1) protease inhibitors (PIs), GRL-04810 and GRL-05010, containing the structure-based designed privileged cyclic ether-derived nonpeptide P2 ligand, bis-tetrahydrofuranylurethane (bis-THF), and a difluoride moiety, both of which are active against the laboratory strain HIV-1LAI (50% effective concentrations [EC50s], 0.0008 and 0.003 μM, respectively) with minimal cytotoxicity (50% cytotoxic concentrations [CC50s], 17.5 and 37.0 μM, respectively, in CD4(+) MT-2 cells). The two compounds were active against multi-PI-resistant clinical HIV-1 variants isolated from patients who had no response to various antiviral regimens. GRL-04810 and GRL-05010 also blocked the infectivity and replication of each of the HIV-1NL4-3 variants selected by up to 5 μM lopinavir (EC50s, 0.03 and 0.03 μM, respectively) and atazanavir (EC50s, 0.02 and 0.04 μM, respectively). Moreover, they were active against darunavir (DRV)-resistant variants (EC50 in 0.03 to 0.034 μM range for GRL-04810 and 0.026 to 0.043 μM for GRL-05010), while DRV had EC50s between 0.02 and 0.174 μM. GRL-04810 had a favorable lipophilicity profile as determined with the partition (log P) and distribution (log D) coefficients of -0.14 and -0.29, respectively. The in vitro blood-brain barrier (BBB) permeability assay revealed that GRL-04810 and GRL-05010 may have a greater advantage in terms of crossing the BBB than the currently available PIs, with apparent penetration indexes of 47.8 × 10(-6) and 61.8 × 10(-6) cm/s, respectively. The present data demonstrate that GRL-04810 and GRL-05010 exert efficient activity against a wide spectrum of HIV-1 variants in vitro and suggest that two fluorine atoms added to their bis-THF moieties may well enhance their penetration across the BBB.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24080647      PMCID: PMC3837900          DOI: 10.1128/AAC.01420-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  54 in total

1.  HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy.

Authors:  Jutta K Neuenburg; Hans R Brodt; Brian G Herndier; Markus Bickel; Peter Bacchetti; Richard W Price; Robert M Grant; Wolfgang Schlote
Journal:  J Acquir Immune Defic Syndr       Date:  2002-10-01       Impact factor: 3.731

2.  Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.

Authors:  Yasuhiro Koh; Shintaro Matsumi; Debananda Das; Masayuki Amano; David A Davis; Jianfeng Li; Sofiya Leschenko; Abigail Baldridge; Tatsuo Shioda; Robert Yarchoan; Arun K Ghosh; Hiroaki Mitsuya
Journal:  J Biol Chem       Date:  2007-07-17       Impact factor: 5.157

3.  Physiochemical drug properties associated with in vivo toxicological outcomes.

Authors:  Jason D Hughes; Julian Blagg; David A Price; Simon Bailey; Gary A Decrescenzo; Rajesh V Devraj; Edmund Ellsworth; Yvette M Fobian; Michael E Gibbs; Richard W Gilles; Nigel Greene; Enoch Huang; Teresa Krieger-Burke; Jens Loesel; Travis Wager; Larry Whiteley; Yao Zhang
Journal:  Bioorg Med Chem Lett       Date:  2008-07-24       Impact factor: 2.823

4.  Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere.

Authors:  A K Ghosh; J F Kincaid; W Cho; D E Walters; K Krishnan; K A Hussain; Y Koo; H Cho; C Rudall; L Holland; J Buthod
Journal:  Bioorg Med Chem Lett       Date:  1998-03-17       Impact factor: 2.823

5.  Dynamics of cellular HIV-1 DNA levels over 144 weeks of darunavir/ritonavir monotherapy versus triple therapy in the MONET trial.

Authors:  Anna Maria Geretti; Jose R Arribas; Erkki Lathouwers; Geraldine M Foster; Rabia Yakoob; Sabine Kinloch; Andrew Hill; Yvon van Delft; Christiane Moecklinghoff
Journal:  HIV Clin Trials       Date:  2013 Jan-Feb

6.  Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.

Authors:  Yasushi Tojo; Yasuhiro Koh; Masayuki Amano; Manabu Aoki; Debananda Das; Sarang Kulkarni; David D Anderson; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

Review 7.  Screening and selecting for optimized antiretroviral drugs: rising to the challenge of drug resistance.

Authors:  Marie-Pierre de Béthune; Kurt Hertogs
Journal:  Curr Med Res Opin       Date:  2006-12       Impact factor: 2.580

8.  Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment.

Authors:  Theresa K Smit; Bruce J Brew; Wallace Tourtellotte; Susan Morgello; Benjamin B Gelman; Nitin K Saksena
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

Review 9.  New patterns of HIV-1 resistance during HAART.

Authors:  E Fumero; D Podzamczer
Journal:  Clin Microbiol Infect       Date:  2003-11       Impact factor: 8.067

10.  Fluorinated Nucleosides: Synthesis and Biological Implication.

Authors:  Peng Liu; Ashoke Sharon; Chung K Chu
Journal:  J Fluor Chem       Date:  2008-09       Impact factor: 2.050

View more
  16 in total

Review 1.  Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.

Authors:  Arun K Ghosh; Heather L Osswald; Gary Prato
Journal:  J Med Chem       Date:  2016-01-22       Impact factor: 7.446

2.  Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications.

Authors:  Masayuki Amano; Pedro Miguel Salcedo-Gómez; Ravikiran S Yedidi; Rui Zhao; Hironori Hayashi; Kazuya Hasegawa; Tomofumi Nakamura; Cuthbert D Martyr; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

Review 3.  Highly resistant HIV-1 proteases and strategies for their inhibition.

Authors:  Irene T Weber; Daniel W Kneller; Andres Wong-Sam
Journal:  Future Med Chem       Date:  2015       Impact factor: 3.808

4.  Potent antiviral HIV-1 protease inhibitor combats highly drug resistant mutant PR20.

Authors:  Daniel W Kneller; Johnson Agniswamy; Arun K Ghosh; Irene T Weber
Journal:  Biochem Biophys Res Commun       Date:  2019-08-29       Impact factor: 3.575

5.  Design of gem-difluoro-bis-tetrahydrofuran as P2 ligand for HIV-1 protease inhibitors to improve brain penetration: synthesis, X-ray studies, and biological evaluation.

Authors:  Arun K Ghosh; Sofiya Yashchuk; Akira Mizuno; Nilanjana Chakraborty; Johnson Agniswamy; Yuan-Fang Wang; Manabu Aoki; Pedro Miguel Salcedo Gomez; Masayuki Amano; Irene T Weber; Hiroaki Mitsuya
Journal:  ChemMedChem       Date:  2014-10-21       Impact factor: 3.466

6.  HIV-Associated Neurocognitive Disorder (HAND) and the Prospect of Brain-Penetrating Protease Inhibitors for Antiretroviral Treatment.

Authors:  Arun K Ghosh; Anindya Sarkar; Hiroaki Mitsuya
Journal:  Med Res Arch       Date:  2017-04-15

7.  A novel tricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor, GRL-0739, effectively inhibits the replication of multidrug-resistant HIV-1 variants and has a desirable central nervous system penetration property in vitro.

Authors:  Masayuki Amano; Yasushi Tojo; Pedro Miguel Salcedo-Gómez; Garth L Parham; Prasanth R Nyalapatla; Debananda Das; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2015-02-17       Impact factor: 5.191

8.  Nature Inspired Molecular Design: Stereoselective Synthesis of Bicyclic and Polycyclic Ethers for Potent HIV-1 Protease Inhibitors.

Authors:  Arun K Ghosh; Margherita Brindisi
Journal:  Asian J Org Chem       Date:  2018-06-08       Impact factor: 3.319

9.  A Modified P1 Moiety Enhances In Vitro Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and In Vitro Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413.

Authors:  Masayuki Amano; Pedro Miguel Salcedo-Gómez; Rui Zhao; Ravikiran S Yedidi; Debananda Das; Haydar Bulut; Nicole S Delino; Venkata Reddy Sheri; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

10.  Design of HIV-1 Protease Inhibitors with Amino-bis-tetrahydrofuran Derivatives as P2-Ligands to Enhance Backbone-Binding Interactions: Synthesis, Biological Evaluation, and Protein-Ligand X-ray Studies.

Authors:  Arun K Ghosh; Cuthbert D Martyr; Heather L Osswald; Venkat Reddy Sheri; Luke A Kassekert; Shujing Chen; Johnson Agniswamy; Yuan-Fang Wang; Hironori Hayashi; Manabu Aoki; Irene T Weber; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2015-08-25       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.